Souhaitez-vous accéder aux communiqués récents ?

BRUXELLES, 20 mai 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, ci-après « SERB », et Hansa Biopharma AB, ci-après « Hansa » (Nasdaq Stockholm : HNSA) annoncent la conclusion d’un accord portant...

BRÜSSEL, May 20, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals („SERB“) und Hansa Biopharma AB („Hansa“) (Nasdaq Stockholm: HNSA) gaben heute bekannt, dass sie eine Vereinbarung getroffen...

SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million

SERB Pharmaceuticals announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.

London, UK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals is pleased to announce the appointment of Dr. Vignesh Rajah as its Chief Medical Officer (CMO). Dr. Rajah brings over two decades...

West Conshohocken, PA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, today announced...

PLEASANTON, CA, March 29, 2025 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal Phase 3 REVERSE-IT trial designed to...

Philadelphia, PA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, is proud to announce that Aurlumyn™ (iloprost) Injection, the first FDA-approved...

Philadelphia, PA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of Aurlumyn™ (iloprost IV), the only FDA approved...

Pleasanton, CA and Philadelphia, PA, Aug. 02, 2024 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB),...